Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

Kohei Takano, Yoichi Munehira, Mana Hatanaka, Ryo Murakami, Yoshihiro Shibata, Takeshi Shida, Kosuke Takeuchi, Sho Takechi, Toshiki Tabata, Takashi Shimada, Shuhei Kishikawa, Yumi Matsui, Osamu Ubukata, Takahiko Seki, Yasuyuki Kaneta

Mol Cancer Ther (2023) 22 (3): 317–332.

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0306

Published: 02 March 2023

View article

Includes: Supplementary data

Journal Articles

Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor

Yasuyuki Kaneta, Takahiro Komatsu, Masashi Miyamoto, Megumi Goto, Hidenori Namiki, Yoshihiro Shibata, Hideaki Kageji, Hiroaki Inagaki, Kiyoshi Nakayama, Yuichi Tominaga, Takeshi Isoyama

Mol Cancer Ther (2018) 17 (1_Supplement): B173.

DOI: https://doi.org/10.1158/1535-7163.TARG-17-B173

Published: 01 January 2018

View article

Journal Articles

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

Shuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka, Hiroko Hitotsumachi, Chihoko Yoshimura, Makoto Kitade, Akihiro Hashimoto, Kenjiro Ito, Akira Gomori, Koichi Takahashi, Yoshihiro Shibata, Akira Kanoh, Kazuhiko Yonekura

Mol Cancer Ther (2015) 14 (1): 14–22.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0219

Published: 13 January 2015

View article

Includes: Supplementary data

Journal Articles

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Yoko Nakatsuru, Hiroaki Ochiiwa, Hiroshi Sootome, Hidenori Fujita, Akihiro Hashimoto, Yoshihiro Shibata, Masato Chiba, Yayoi Fujioka, Kazuhiro Yonekura, Hiroshi Hirai, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): A272.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-A272

Published: 01 November 2013

View article

Journal Articles

Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.

Masanori Kato, Kazutaka Miyadera, Yoshihiro Shibata, Kimihiro Ito, Yoshimi Aoyagi, Masato Chiba, Kazuhiko Yonekura, Yoshikazu Iwasawa, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): C112.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-C112

Published: 01 November 2013

View article

NARROW

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.

Email alerts

AACR Journals

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only